Estropipate
| Clinical data | |
|---|---|
| Trade names | Harmogen, Improvera, Ogen, Ortho-Est, Sulestrex, others |
| Other names | Piperazine estrone sulfate; Estrone sulfate piperazine salt; Pipestrone |
| AHFS/Drugs.com | Monograph |
| Routes of administration | By mouth |
| Drug class | Estrogen; Estrogen ester |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.027.906 |
| Chemical and physical data | |
| Formula | C22H32N2O5S |
| Molar mass | 436.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Estropipate, also known as piperazine estrone sulfate and sold under the brand names Harmogen, Improvera, Ogen, Ortho-Est, and Sulestrex among others, is an estrogen medication which is used mainly in menopausal hormone therapy in the treatment of menopausal symptoms. It is a salt of estrone sulfate and piperazine, and is transformed into estrone and estradiol in the body. It is taken by mouth.